Home
Everest Medicines

Everest Medicines Market Share Analysis for July 2026

Health > Biotechnology and Pharmaceuticals

Domaineverestmedicines.com

Year Founded2017

Employees201 - 500

Annual Revenue$5M - $10M

Everest Medicines

Everest Medicines (including company regionals)

everestmedicines.com

See more website traffic and engagement information

Everest Medicines Revenue up to July 2026 is 5M - 10M

revenue generated by Everest Medicines top domains

Everest Medicines top domains revenue over 3 years

Revenue for Everest Medicines top domains

everestmedicines.com5M - 10M

See more with Sales Intelligence

Total visits to Everest Medicines's top domains

Understand Everest Medicines market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

everestmedicines.com64.1K

See more with Sales Intelligence

Avg. visit duration in Everest Medicines's top domains

Analyze Everest Medicines engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

everestmedicines.com00:15:23

See more with Sales Intelligence

Avg. pageviews on Everest Medicines's top domains

See how Everest Medicines keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

everestmedicines.com13.74

See more with Sales Intelligence

Everest Medicines top competitors by domain

Top similar sites in July 2026, ranked by their affinity

lindushealth.comCompany NameLindus Health LimitedEmployees51 - 200HQUnited Kingdom, LondonAnnual revenue$25M - $50MTotal visits41.2KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Everest Medicines

These are the website technologies, by industry, used by Everest Medicines top domains

Mobile (3)

Meta Viewport

Email Services (1)

Microsoft Exchange Online

Multilingual (1)

Multilingual Support

News & Signals from Everest Medicines

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsEverest Medicines is developing DMX-200.The payment, worth approximately A$14.1 million, is the first instalment under an agreement that gives Everest exclusive rights to develop and commercialise DMX-200 across Greater China, South Korea and selected Southeast Asian markets.

NewsEverest Medicines had revenue of $170M on Jun 30th '26.Everest Medicines reported revenue of RMB1,147.8m for the six months ended 30 June 2026, marking a 157.3% increase compared to RMB446.1m in the same period of 2025.

NewsEverest Medicines Limited partnered with Dimerix Limited on Jun 16th '26.HONG KONG, Jun 16, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited ("Dimerix"), for the development and commercialization of DMX-200 in Greater China (Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan region), South Korea and certain Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam and Philippines).